Immunomedics,Inc. (NASDAQ:IMMU) Files An 8-K Other Events
Item 8.01 Other Events.
On January9, 2017, the Company issued a press release titled
Immunomedics Announces Reconstituted Board of Directors and
Leadership Succession Plan. The full text of the press release is
attached to this current report on Form8-K as Exhibit99.1 hereto
and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit No. |
|
DescriptionofExhibit |
|
99.1 |
Press Release of Immunomedics,Inc., dated January9, 2017, |
About Immunomedics, Inc. (NASDAQ:IMMU)
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials. Immunomedics, Inc. (NASDAQ:IMMU) Recent Trading Information
Immunomedics, Inc. (NASDAQ:IMMU) closed its last trading session down -0.25 at 3.48 with 878,721 shares trading hands.
